Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements review identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://walti653jln4.ssnblog.com/profile